Sanofi becomes latest drugmaker to announce insulin price cuts, capping cost at $35 for the privately insured

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday. The change is effective January 1.